Targets of anticytokine therapy and the risk of infections in humans and mice

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 626-635

  Van De Vosse, Esther ^a   Van Agtmael, Michiel A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Deficiency; Interferons; Interleukins; Knockout; Mice; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTAGONIST; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR BLOCKER; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC DISORDER; GENETIC MANIPULATION; GRANULOMA; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KNOCKOUT MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; VIRUS INFECTION; VIRUS REACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFLAMMATION; INTERFERONS; INTERLEUKINS; MICE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34948886115     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f05c6d     Document Type: Review

References (71)

1. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54:2817-2829. Clinical trial to determine safety and efficacy of IL-6 receptor antagonist as therapy for rheumatoid arthritis. Severe infections were only observed in groups treated with the antagonist (with or without methotrexate); the numbers of patients and duration of the study (16 weeks) was too short to determine infection risk, however.
2. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52:2585-2588.
3. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of antiinterferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001; 30:203-207.
4. Mannon PJ, Fuss IJ, Mayer L, et al. Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-2079.
5. Moiton MP, Richez C, Dumoulin C, et al. Role of antitumour necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect 2006; 12:1151-1153. Review of infection risks as reported in various clinical trials of rheumatoid arthritis patients treated with TNF-blockers.
6. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36:159-167. The authors provide a comprehensive review of the role of TNF and the working mechanisms of TNF antagonists. Special emphasis is given to granuloma formation and the granulomatous infections associated with the use of TNF antagonists.
7. Wondergem MJ, Voskuyl AE, van Agtmael MA. A case of legionellosis during treatment with a TNFα antagonist. Scand J Infect Dis 2004; 36:310-311.
8. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-α antagonists. Clin Infect Dis 2006; 43:e95-e100. Comparison of Legionella infections during anti-TNF therapy with infections in a French population reveals highly increased Legionella infection risk.
9. Mufti AH, Toye BW, Mckendry RRJ, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor a inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor a inhibitor use. Diagn Microbiol Infect Dis 2005; 53:233-238.
10. Rijkeboer A, Voskuyl A, van Agtmael M. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-α antagonist. Scand J Infect Dis 2007; 39:80-83.
11. Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-α therapy. J Clin Rheumatol 2007; 13:150-152.
12. Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis 2007; 44:e82-e84.
13. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285. A very thorough meta-analysis of the risk of developing malignancies or severe infections as reported in clinical trials with TNF-blockers in patients with rheumatoid arthritis. The odds ratios calculated were 3.3 and 2.0, respectively.
14. Cvetkovic RS, Keating G. Anakinra. Biodrugs 2002; 16:303-311.
15. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-1012. The first long-term safety analysis of IL-1 receptor antagonist-treated patients with rheumatoid arthritis in a clinical trial; no increased risk of infections was found.
16. Kone-Paut I, Retornaz K, Garnier JM, Bader-Meunier B. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra). Clin Exp Rheumatol 2007; 25:119.
17. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43:2648-2659.
18. Feige U, Hu YL, Gasser J, et al. Antiinterleukin-1 and antitumor necrosis factor-a synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000; 57:1457-1770.
19. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-1419.
20. Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised antiinterleukin-6 receptor monoclonal antibody. Ann Rheum Dis 2006; 65:1667-1669. First and only report of a fatal infection during treatment with IL-6 receptor antagonist.
21. Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 2005; 64:iv24-iv28.
22. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003; 14:185-191.
23. Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005; 7:1-18.
24. Ali S, Vollaard AM, Martina CA, et al. Polymorphisms in pro-inflammatory genes and susceptibility to typhoid fever and paratyphoid fever. J Interferon Cytokine Res 2007; 27:271-280.
25. Sainz J, Perez E, Hassan L, et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007; 68:41-50.
26. Chakravorty M, Ghosh A, Choudhury A, et al. Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 2007; 27:411-419.
27. Hirankarn N, Kimkong I, Kummee P, et al. Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 2006; 12:776-779.
28. Chan AO, Chu KM, Huang C, et al. Association between Helicobacter pylori infection and interleukin 1β polymorphism predispose to CpG island methylation in gastric cancer. Gut 2007; 56:595-597.
29. Vonk AG, Netea MG, van Krieken JH, et al. Endogenous interleukin (IL)-1α and IL-1β are crucial for host defense against disseminated candidiasis. J Infect Dis 2006; 193:1419-1426. In this systematic study, susceptibility to C. albicans was analyzed and compared in IL-1α, IL-1β and double knockout mice. IL-1α and IL-1β were shown to be essential for a protective response, where IL-1β recruits polymorphonuclear neutrophils to the site of infection and IL-1α is important for subsequent degranulation of these polymorphonuclear neutrophils needed to damage Candida pseudohyphae.
30. Gebhard F, Pfetsch H, Steinbach G, et al. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 2000; 135:291-295.
31. Carrol ED, Thomson AP, Jones AP, et al. A predominantly anti-inflammatory cytokine profile is associated with disease severity in meningococcal sepsis. Intensive Care Med 2005; 31:1415-1419.
32. Carsin H, Assicol M, Feger F, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNFα and endotoxin levels early after thermal injury. Burns 1997; 23:218-224.
33. Castellucci L, Menezes E, Oliveira J, et al. IL6-174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis 2006; 194:519-527. The authors performed a case-control study to determine the influence of an IL-6 promoter polymorphism on susceptibility to Leishmaniasis and confirmed their findings in a family-based study group to exclude false-positive results due to ethnic admixture. In-vitro cytokine production data of stimulated macrophages support their findings.
34. Lehrnbecher T, Bernig T, Hanisch M, et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005; 19:1745-1750.
35. Leon LR, White AA, Kluger MJ. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol Regul Integr Comp Physiol 1998; 275:R269-R277.
36. Wang Q, Fang CH, Hasselgren PO. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1013-R1023.
37. Deutschman CS, Cereda M, Ochroch EA, Raj NR. Sepsis-induced cholestasis, steatosis, hepatocellular injury, and impaired hepatocellular regeneration are enhanced in interleukin-6-/- mice. Crit Care Med 2006; 34:2613-2620. In a sepsis model using cecal ligation and puncture, male IL-6-/- mice rapidly succumbed (90% within 72 h) and, in a severe sepsis model using double puncture, all IL6-/- mice died within 12 h. The study shows the essential role of IL-6 in controlling/modulating the septic response and in hepatic regeneration.
38. Remick DG, Bolgos G, Copeland S, Siddiqui J. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-2757.
39. Morales-Montor J, Baig S, Kabbani A, Damian R. Do interleukin-6 and macrophage-migration inhibitory factor play a role during sex-associated susceptibility in murine cysticercosis? Parasitol Res 2002; 88:901-904.
40. Morales-Montor J, Baig S, Mitchell R, et al. Immunoendocrine interactions during chronic cysticercosis determine male mouse feminization: role of IL-6. J Immunol 2001; 167:4527-4533.
41. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-780.
42. lo (naïve) cells that are ITK-dependent. Double knockout mice do not have CD8+ T cells.
43. Combe CL, Moretto MM, Schwartzman JD, et al. Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. Proc Natl Acad Sci USA 2006; 103:6635-6640. Using T. gondii infection in IL-15-/- mice using oral and intraperitoneal infection, the authors clearly show the influence of the route of infection on the outcome.
44. Lieberman LA, Villegas EN, Hunter CA. Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii. Infect Immun 2004; 72:6729-6732.
45. Dann SM, Wang HC, Gambarin KJ, et al. Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis 2005; 192:1294-1302.
46. Schluns KS, Williams K, Ma A, et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827-4831.
47. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195:1541-1548.
48. Obar JJ, Crist SG, Leung EK, Usherwood EJ. IL-15-independent proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus infection. J Immunol 2004; 173:2705-2714.
49. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-γ gene is important for interferon-μ-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007; 104:985-990.
50. Ottenhoff THM, Verreck FAW, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis 2005; 85:53-64.
51. Mansouri D, Adimi P, Mirsaeidi M, et al. Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 2005; 164:753-757.
52. Chantrain CF, Bruwier A, Brichard B, et al. Successful hematopoietic stem cell transplantation in a child with active disseminated Mycobacterium fortuitum infection and interferon-γ receptor 1 deficiency. Bone Marrow Transplant 2006; 38:75-76.
53. Remiszewski P, Roszkowska-Sliz B, Winek J, et al. Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFNγR1 deficiency. Respiration 2006; 73:375-378.
54. Yamamoto T, Kita M, Ohno T, et al. Role of tumor necrosis factor-alpha and interferon-gamma in Helicobacter pylori Infection. Microbiol Immunol 2004; 48:647-654.
55. Martin ME, Caspersen K, Dumler JS. Immunopathology and ehrlichial propagation are regulated by Interferon-γ and Interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol 2001; 158:1881-1888.
56. Barton ES, White DW, Cathelyn JS, et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007; 447:326-329. The authors show that latent infection with a β- or a γ-herpesvirus provides IFN-γ-dependent crossprotection from bacterial infection. These findings will initiate many different types of research into the beneficial aspect of viral latency and may have great impact on the consideration of immunization strategies against viral infections.
57. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-276.
58. Hoeve MA, de Boer T, Langenberg DML, et al. IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor β1 deficiency. Eur J Immunol 2003; 33:3393-3397.
59. Verreck FA, de Boer T, Langenberg DML, et al. Human IL-23 producing type-1 macrophages promote but IL-10 producing type-2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004; 101:4560-4565.
60. Hoeve MA, Savage NDL, de Boer T, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006; 36:661-670. The authors show IL-12 and IL-23 not only have divergent effects, but even opposed effects, on IL-17 and IFN-γ production in human T cells, revealing an antiinflammatory role for IL-12.
61. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
62. Van de Vosse E, Ottenhoff THM. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23 dependent signaling that affect innate and adaptive immunity. Microbes Infect 2006; 8:1167-1173. A review of the infections observed in IL-12p40- and IL-12Rβ1-deficient patients and analysis of the specific role of IL-12/IL-23 signalling in immunity to salmonella and mycobacterial infections.
63. Sanal O, Turkkani G, Gumruk F, et al. A case of interleukin-12 receptor β-1 deficiency with recurrent Leishmaniasis. Pediatr Infect Dis J 2007; 26:366-368.
64. Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J Immunol 2005; 175:788-795.
65. Chackerian AA, Chen SJ, Brodie SJ, et al. Neutralization or absence of the interleukin -23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006; 74:6092-6099. In this paper, the response in mouse knockouts for IL-12p40, IL-12p35, and IL-23p19 are compared. IL-23p19 is not required for bacterial control, granuloma formation, or memory response, while IL-12p40 and IL-12p35 are, demonstrating IL-23p19 is not essential for host defense against mycobacterial infection.
66. Lehmann J, Bellmann S, Werner C, et al. IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J Immunol 2001; 167:5304-5315.
67. Holscher C, Atkinson RA, Arendse B, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001; 167:6957-6966.
68. Dybing JK, Walters N, Pascual DW. Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections. Infect Immun 1999; 67:6242-6248.
69. Franklin CL. Microbial considerations in genetically engineered mouse research. ILAR J 2006; 47:141-155. An excellent discussion of the many type of effects that may be observed upon desired and undesired interaction of microbes with genetically engineered mice. Required reading for anyone working with mice, whether genetically deficient or not. Special attention is given to the pathogens prevalent in mouse colonies.
70. Denis M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J Leukoc Biol 1991; 50:495-501.
71. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195:1643-1650. The authors compared the effect of 'mouse etanercept' to 'mouse infliximab' in a mouse model of latent TB (mice chronically infected with M. tuberculosis). These long overdue experiments may explain the difference in TB reactivation, as they showed reduced penetration of mouse etanercept compared to mouse infliximab into the granulomas.